Drug Profile


Alternative Names: DE 081; WEB 2086; WEB 2086BS

Latest Information Update: 18 May 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Anti-inflammatories; Antiarrhythmics; Antiasthmatics; Antiplatelets; Morpholines
  • Mechanism of Action Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Allergic rhinitis; Asthma; Pancreatitis; Thrombosis
  • Discontinued Allergic conjunctivitis; Arrhythmias; Peptic ulcer; Transplant rejection

Most Recent Events

  • 31 Dec 2003 Discontinued - Phase-II for Allergic conjunctivitis in Japan (unspecified route)
  • 10 Oct 2003 This compound is still in active development
  • 31 Mar 2001 Phase-II clinical trials for Allergic conjunctivitis in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top